<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599830</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01041-54</org_study_id>
    <nct_id>NCT03599830</nct_id>
  </id_info>
  <brief_title>Study of the Cognition of Patients Treated With Immunotherapy</brief_title>
  <acronym>COG-IMMUNO</acronym>
  <official_title>Study of the Cognition of Patients Treated With</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's longitudinal pilot study aims to evaluate for the first time the impact of
      immunotherapy on cognition in oncology.

      Due to the recent nature of immunotherapy, its side effects and impact on quality of life are
      still poorly understood and, to date, there is no published study evaluating the impact of
      immunotherapy on cognition in patients treated for cancer.

      The study consists of the passation of 3 neuropsychological assessments over a period of 6
      months in cancer patients who start immunotherapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive function (at least in a cognitive domain)</measure>
    <time_frame>between inclusion and 3 months.</time_frame>
    <description>The proportion of patients who will have a reduction of scores in neuropsychological questionnaires (scores of MoCA2, Hopkins verbal learning test, WAIS-IV, Trail Making test, Stroop Symboles)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Cancer Who Start Immunotherapy</condition>
  <condition>All Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cognitive test passations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 neuropsychological passations over a period of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive test passations</intervention_name>
    <description>Tests :
MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences</description>
    <arm_group_label>Cognitive test passations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over the age of 18,

          -  Patient with cancer and having to initiate treatment with immunotherapy alone

          -  Treatment with immunotherapy will include either an anti-PD1 / L1 or Anti CTLA4
             monotherapy or combination,

          -  Patients may have received other antitumor treatments other than immunotherapy but
             these should be stopped at the time of initiation of immunotherapy

          -  Performance Status &lt;2

          -  Patient at the level of studies 3 &quot;end of primary studies&quot; minimum (Barbizet scale),

          -  Mastery of the French language.

          -  Patient affiliated to a social security system

          -  Patient having attested in writing of his non-opposition to participate in the study

        Exclusion Criteria:

          -  Previous treatment with immunotherapy

          -  Another anti-tumor treatment underway

          -  Primary cancer of the central nervous system or cerebral metastasis, symptomatics and
             not controlled

          -  Abuse of alcohol or drug use

          -  Severe visual and / or auditory deficiency,

          -  Refusal of participation of the patient.

          -  Patient deprived of liberty or under guardianship

          -  Patient unable to follow the study for geographical, social or psychopathological
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence JOLY, Prof</last_name>
    <phone>0231455050</phone>
    <email>f.joly@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu BOONE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure CESAIRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MORTIER, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Cognition</keyword>
  <keyword>Cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

